BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Business

  Endologix Reports Fourth Quarter and Fiscal Year 2018 Financial Results

  Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced financial results for the fourth quarter and fiscal year ended December 31, 2018.

  February 25, 2019

   · 

  15 min read
• Deals

  Sage Therapeutics Announces Proposed Public Offering of Common Stock - February 25, 2019

  Sage Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, announced that it has commenced an underwritten public offering of $500,000,000 of its common stock.

  February 25, 2019

   · 

  3 min read
• BioCapital

  Sirnaomics to Present Data Demonstrating STP705 Augmentation of Immune Checkpoint Inhibitors in Liver Cancer Animal Model at AsiaTIDES

  Sirnaomics, Inc. announced that the Company will present preclinical data from the use of its RNAi technology program in a liver cancer mouse model at AsiaTIDES: Ogligonucleotide & Peptide Therapeutics taking place in Tokyo, Japan on February 28 - March 1, 2019.

  February 25, 2019

   · 

  2 min read
• Policy

  FDA responds to safety signal reported in required postmarketing trial for Xeljanz

  Today the FDA is warning about a safety signal that emerged in a required postmarketing trial of the drug Xeljanz in patients with rheumatoid arthritis.

  February 25, 2019

   · 

  4 min read
• Biotech Beach

  Dexcom Announces Upcoming Conference Presentation - February 25, 2019

  DexCom, Inc. announced that management will present an update on Dexcom at the following upcoming investor conference

  February 25, 2019

   · 

  1 min read
• Business

  Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

  Recently Presented NAM-NK and NiCord Data at 2019 TCT Annual Meeting Demonstrate Clinical Progress and Potential of Proprietary NAM Expansion Technology

  February 25, 2019

   · 

  13 min read
• Business

  Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Results

  Medpace Holdings, Inc. announced financial results for the fourth quarter and full year ended December 31, 2018.

  February 25, 2019

   · 

  33 min read
• Business

  Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2019

  Global Cord Blood Corporation announced its unaudited financial results for the third quarter and first nine months of fiscal year 2019 ended December 31, 2018.

  February 25, 2019

   · 

  22 min read
• Business

  Xencor Reports Fourth Quarter and Full Year 2018 Financial Results

  Initial Data from Phase 1 Study of XmAb®14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on Partial Clinical Hold Pending Resolution with FDA

  February 25, 2019

   · 

  16 min read
• Business

  Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook

  Veracyte, Inc. announced financial results and business progress for the quarter and full year ended December 31, 2018, and provided financial guidance for 2019.

  February 25, 2019

   · 

  16 min read